BioSpace News Archive

Biotech Beach

Micro Medical Solutions Marks First U.S. Implants of MicroStent for Peripheral Artery Disease

A clinical trial is underway for the MicroStent microvascular device, which is designed to open occluded arteries and prevent below-the-knee amputations.

June 7, 2018
·
3 min read
FDA

U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation

U.S. New Drug Application Granted FDA Priority Review

June 7, 2018
·
9 min read
Biotech Bay

BioMarin Receives Milestone Payments from Pfizer for Talazoparib

BioMarin Pharmaceutical Inc. announced that the Company received $20 million in milestone payments from Pfizer Inc.

June 7, 2018
·
2 min read
Business

Stallergenes Greer Provides Business Update and Refines Its 2018 Financial Outlook

Company now expects 2018 net sales to be in the range of €270 million to €280 million and EBITDA to be in the range of €40 million to €50 million.

June 7, 2018
·
6 min read
Business

CENTOGENE Partners with the Universities of Greifswald and Rostock to Develop Fast-Tracked Diagnostic Workflow for Personalized Immune-based Therapies for Colon and Pancreatic Tumors

CENTOGENE is committed to developing a fast-track diagnostic workflow which lays the groundwork for individualized vaccination therapy in cancer.

June 7, 2018
·
3 min read
Business

Egalet Appoints Industry Veteran John Varian to Board of Directors

Varian most recently served as the CEO and director of XOMA, an antibody business, where he led the refocusing and refinancing of the company

June 7, 2018
·
5 min read
Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF

Data from KALYDECO® (ivacaftor) studies show the potential to modify the long-term progression of the disease

June 7, 2018
·
21 min read
Mictoryl® Pediatric (propiverine hydrochloride) now covered by several public drug plans to treat symptoms associated with overactive bladder

Indicated for the symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in pediatric patients, from the age of 5 years, with overactive bladder.

June 7, 2018
·
1 min read
Policy

OmniLytics, Inc. and Certis USA Join Forces to Develop and Market New Bacterial Disease Control Products in Agriculture

OmniLytics has entered into an exclusive U.S. sales and marketing collaboration with Certis USA, LLC for its AgriPhage line of biopesticides.

June 7, 2018
·
3 min read
Genetown

FDA, Bill & Melinda Gates Foundation and the Gates MRI Headline Final Day of BIO International Convention

Fireside chats with Dr. Scott Gottlieb, Dr. Sue Desmond-Hellman and Dr. Penny Heaton focus on U.S. and global healthcare challenges

June 7, 2018
·
3 min read